AbbVie Contract Manufacturing AbbVie Contract Manufacturing

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Fred Hutchinson Cancer Center.

    Client Virtual Booth

    FRED HUTCHINSON CANCER CENTER

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Fred Hutchinson Cancer Center
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1100 Fairview Avenue N., Seattle, WA 98109
    Telephone
    Telephone
    +1 206.667.4399
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.fredhttps://twitter.com/fredhutchhutch.org/en.html
    Linkedin
    Linkedin
    https://www.linkedin.com/company/fred-hutchinson-cancer-research-center/
    Twitter
    Twitter
    https://twitter.com/fredhutch

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Kineta Announces New Research Agreement to Evaluate VISTA Biomarker Expression

    Details:

    The agreement aims to evaluate VISTA expression as a potential biomarker in cancer patients from Kineta’s ongoing Phase 1/2 clinical trial evaluating KVA12123, the company’s VISTA blocking immunotherapy, alone and in combination with pembrolizumab.


    Lead Product(s): KVA12123,Pembrolizumab

    Therapeutic Area: Oncology Product Name: KVA12123

    Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule

    Recipient: Kineta

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement September 18, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Mustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous C...

    Details:

    MB-106 (CD20-targeted autologous CAR T Cell Therapy) which plays a role in the differentiation of B-cells into plasma cells for patients with follicular lymphoma.


    Lead Product(s): MB-106

    Therapeutic Area: Oncology Product Name: MB-106

    Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy

    Recipient: Mustang Bio

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable June 15, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    transo-pharm-handels-gmbh-m-2024-05-20

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search